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ABSTRACT
OBJECTIVE
To comparatively examine differences in risk of clinical
manifestations and death among people admitted to
hospital with coronavirus disease 2019 (covid-19) and
seasonal influenza.
DESIGN
Cohort study.
SETTING
US Department of Veterans Affairs.
PARTICIPANTS
Patients admitted to hospital with covid-19 between
1 February 2020 and 17 June 2020 (n=3641)
and seasonal influenza between 2017 and 2019
(n=12 676).
MAIN OUTCOME MEASURES
Risks of clinical manifestations, healthcare resource
use (including use of mechanical ventilation,
admission to intensive care, and length of stay), and
death, estimated using a doubly robust approach to
build propensity scores that were then used along
with covariates to adjust the outcome models.
RESULTS
Compared with seasonal influenza, covid-19 was
associated with higher risk of acute kidney injury
(odds ratio 1.52, 95% confidence interval 1.37 to
1.69), incident renal replacement therapy (4.11, 3.13
to 5.40), incident insulin use (1.86, 1.62 to 2.14),
severe septic shock (4.04, 3.38 to 4.83), vasopressor

WHAT IS ALREADY KNOWN ON THIS TOPIC
Covid-19 is an emerging infectious disease caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), of which the predominant clinical
presentation is respiratory disease
Evidence is accumulating that it is associated with extrapulmonary
manifestations and high risk of healthcare use and death
Comparisons of clinical manifestations and mortality between covid-19 and
seasonal influenza have been made using disparate data and statistical methods
and do not represent “apples with apples” comparisons

WHAT THIS STUDY ADDS
Among people admitted to hospital, compared with seasonal influenza,
covid-19 was associated with increased risk of various extrapulmonary clinical
manifestations
Covid-19 was also associated with increased health resource use, including
mechanical ventilator use, admission to intensive care, and length of hospital
stay, and nearly five times the risk of death
The differences in death rates between covid-19 and seasonal influenza were
most manifest in older adults with kidney disease or dementia and black people
with obesity, diabetes, or kidney disease
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use (3.95, 3.46 to 4.51), pulmonary embolism
(1.50, 1.18 to 1.90), deep venous thrombosis (1.50,
1.20 to 1.88), stroke (1.62, 1.17 to 2.24), acute
myocarditis (7.82, 3.53 to 17.36), arrythmias and
sudden cardiac death (1.76, 1.40 to 2.20), elevated
troponin (1.75, 1.50 to 2.05), elevated aspartate
aminotransferase (3.16, 2.91 to 3.43), elevated
alanine aminotransferase (2.65, 2.43 to 2.88), and
rhabdomyolysis (1.84, 1.54 to 2.18). Compared with
seasonal influenza, covid-19 was also associated with
higher risk of death, mechanical ventilator use, and
admission to intensive care (hazard ratio 4.97, (95%
confidence interval 4.42 to 5.58), 4.01 (3.53 to 4.54),
and 2.41 (2.25 to 2.59), respectively) and 3.00 (2.20
to 3.80) additional days of hospital stay. Differences
in rates of death per 100 patients between covid-19
and seasonal influenza were most pronounced in
people over 75 years of age with chronic kidney
disease or dementia and those with black race and
obesity, diabetes, or chronic kidney disease.
CONCLUSIONS
Among people admitted to hospital, compared with
seasonal influenza, covid-19 was associated with
increased risk of extrapulmonary organ dysfunction,
death, and increased health resource use. The
findings may inform the global discussion about the
comparative risks of covid-19 and seasonal influenza
and may help the ongoing effort to manage the
covid-19 global pandemic.

Introduction
The coronavirus disease 2019 (covid-19) global
pandemic might be the most challenging health
crisis of our lifetime. The number of infected people
and number of deaths continue to grow worldwide.1
Comparisons of clinical manifestations and mortality
between covid-19 and seasonal influenza have been
drawn by public health officials, policy makers, and
the public at large. However, these comparisons have
so far relied on data and mortality statistics obtained
by disparate methods and are not based on an “apples
with apples” comparison.2 A robust comparative
approach would allow stakeholders to develop a
deeper understanding of the health risks of covid-19
(compared with the well known seasonal influenza)
and to anticipate demand for healthcare services and
project mortality with greater accuracy.
In this study, we leveraged the breadth and depth
of the electronic healthcare databases of the US
Department of Veterans Affairs (VA), which operates
the largest nationally integrated healthcare delivery
system in the US, to do a comparative evaluation
of clinical manifestations and outcomes among
1
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Comparative evaluation of clinical manifestations and risk
of death in patients admitted to hospital with covid-19 and
seasonal influenza: cohort study
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Methods
Setting
We used the electronic healthcare databases of the
US Department of Veterans Affairs, which operates
the largest nationally integrated healthcare system
in the United States—a veteran specific national
health service—to discharged veterans of the US
armed forces. The US Department of Veterans Affairs
provides care at 1255 healthcare facilities, including
170 VA medical centers (hospital systems) and
1074 outpatient sites of care of varying complexity
(Veterans Health Administration outpatient clinics)
to more than nine million veterans enrolled in the VA.
All enrolled veterans have access to the Department
of Veterans Affairs’ comprehensive medical benefits
package including inpatient hospital care; outpatient
services; preventive, primary, and specialty care;
prescriptions; mental healthcare; home healthcare;
geriatric and extended care; medical equipment; and
prosthetics.
Cohort
We selected patients from the Department of Veterans
Affairs healthcare system with a positive laboratory
test result for influenza between 1 January 2017 and
31 December 2019 (n=54 281) or with a positive
laboratory test for covid-19 between 1 February 2020
and 17 June 2020 (n=9125). We identified patients
with a hospital admission between five days before
and 30 days after the positive test result (n=12 748 in
seasonal influenza group; n=3641 in covid-19 group).
For participants with both seasonal influenza and
covid-19 hospital admission records (n=72), we used
their first covid-19 admission records in the analyses.
The final cohort consisted of 16 317 participants,
including 12 676 participants in the seasonal influenza
group and 3641 participants in the covid-19 group
(supplementary figure S1). We defined time zero as the
date of admission to hospital and followed participants
until the first occurrence of 60 days after admission,
death, or end of study follow-up (17 June 2020). After
60 days of follow-up, 168 (1.33%) patients in the
seasonal influenza group and 76 (2.08%) patients
in the covid-19 group remained in hospital. The
probability of patients remaining in hospital in the two
groups is provided in supplementary figure S2.
Data sources
The Department of Veterans Affairs Corporate Data
Warehouse (CDW) provided electronic health records
from participants enrolled in the VA healthcare
system.3-6 We used the CDW laboratory results domain
2

to collect laboratory test information and the CDW
inpatient encounters domains to collect information
including diagnoses, procedures, and other aspects
of healthcare use during a hospital admission.7
We used the CDW pharmacy domain and CDW bar
code medication administration domain to collect
medication data and the CDW vital signs domain to
collect vital measurements. We collected demographic
information from the CDW patient domain and VA vital
status database, as well as disease history from both
the CDW inpatient encounter and outpatient encounter
domains.8-10

Exposures
Exposures in the study were admission to hospital with
seasonal influenza and admission to hospital with
covid-19, defined on the basis of a positive laboratory
test result for seasonal influenza or covid-19 with a
hospital admission within five days before the test or
within 30 days after the test.
Outcomes
The primary outcome of the study was time until
death since hospital admission. We defined clinical
outcomes including acute kidney injury, incident renal
replacement therapy, incident insulin use, severe
septic shock, vasopressor use, pulmonary embolism,
deep venous thrombosis, stroke, acute myocarditis,
arrythmias and sudden cardiac death, elevated
troponin, elevated aspartate aminotransferase, elevated
alanine aminotransferase, and rhabdomyolysis
by using definitions based on laboratory data
and diagnostic and procedure codes.6 11-18
Outcomes related to healthcare use included time
until mechanical ventilation, time until admission to
intensive care unit (ICU), and length of stay in hospital,
which we defined as days from admission until first
discharge among patients discharged from hospital.
Covariates
Covariates in the study included demographics such
as age, race (white, black, and other), and sex; history
of diseases such as chronic lung disease, cancer,
cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, and
peripheral artery disease; history of use of drugs such
as statins, angiotensin converting enzyme inhibitors or
angiotensin receptor blockers, and non-steroidal antiinflammatory drugs; smoking status (never, former,
and current); and estimated glomerular filtration rate
and body mass index (underweight <18.50, normal
≥18.50-<25, overweight ≥25-<30, and obese ≥30)
calculated from height and weight. We ascertained
disease history during the year before admission to
hospital and defined outpatient drug use by a record
of prescription that provided medication within the
30 days before the admission. We selected estimated
glomerular filtration rate and body mass index from
the measurement before and closest to the admission.
When values of covariates were missing (0.18% of
age, 2.56% of estimated glomerular filtration rate,
doi: 10.1136/bmj.m4677 | BMJ 2020;371:m4677 | the bmj
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US veterans admitted to hospital with covid-19
and seasonal influenza. This approach provides
a comparative assessment between covid-19 and
seasonal influenza and will inform the global
discussion and effort to manage current and future
waves of this global pandemic in which some waves
might spatiotemporally coincide with seasonal
influenza.
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Statistical analyses
We present the mean and standard deviation, frequency
and percentage, or median and interquartile range, as
appropriate, of the characteristics for patients admitted
to hospital with seasonal influenza and covid-19. We
made between group comparisons using χ2 tests for
counts and t tests for continuous variables.
We used logistic regressions to examine the
difference in clinical manifestations between seasonal
influenza and covid-19. We estimated excess events
per 100 patients based on difference in the probability
of the event occurring if all participants had a hospital
admission for covid-19 compared with if all participants
had a seasonal influenza related admission. To adjust
for confounding, we used doubly robust estimation
for all models. We built a propensity score based on
covariates including age, sex, race, smoking status,
body mass index, estimated glomerular filtration rate,
chronic lung diseases, cancer, cardiovascular diseases,
cerebrovascular disease, dementia, diabetes mellitus,
hypertension, peripheral artery disease, and use of
statins, angiotensin converting enzyme inhibitors or
angiotensin receptor blockers, and non-steroidal antiinflammatory drugs. Doubly robust estimation adjusted
for both the covariates and the propensity score in the
outcome models.19 20 To evaluate the likelihood of
violation of the positivity assumption, we plotted the
propensity score distributions in two exposure groups
(supplementary figure S3). We examined the balance
of baseline characteristics between the covid-19 group
and seasonal influenza group, and the result suggested
that balance was achieved with the application of the
propensity score (supplementary figures S3 and S4;
supplementary table S1).
We constructed survival models with doubly robust
estimation to examine the difference in risk of death
between hospital admission for covid-19 and hospital
admission for seasonal influenza. We estimated risk
of mechanical ventilator use and admission to ICU on
the basis of the Fine and Gray survival model, in which
death before the occurrence of the event was considered
a competing risk.21 For all survival outcomes, we
evaluated proportional hazard assumptions and
observed no indication of violation (supplementary
figure S5). We estimated excess outcomes per 100
patients on the basis of the differences in cumulative
incidence at 60 days if all participants had a
hospital admission for covid-19 compared with if all
participants had a hospital admission for seasonal
the bmj | BMJ 2020;371:m4677 | doi: 10.1136/bmj.m4677

influenza.13 We also used linear regression to examine
the difference in length of stay in patients discharged
from hospital.
We aimed to identify groups of participants that were
at the highest risk of death due to covid-19, as well as
those groups that had the highest disparities between
risk of death due to covid-19 and seasonal influenza.
We did further survival analyses to investigate risk
of death by comorbid condition and demographics
(age ≤65, >65-≤75, >75; white, black race) pairs. We
estimated death rates per 100 participants on the basis
of the cumulative incidence function at 60 days if all
participants had a hospital admission for covid-19 with
a defined comorbid condition and demographic pair
(for example, rate of death in those aged ≤65 and with
cardiovascular disease). We then estimated differences
in death rates between hospital admission for covid-19
and hospital admission for seasonal influenza under
each condition pair. Results are presented in heat
maps, colored by the rate of death.
We did sensitivity analyses to test the robustness
of the results. We estimated the risk (hazard ratios)
of death, mechanical ventilation, and admission to
ICU for covid-19 versus seasonal influenza in each
influenza season included in the cohort (influenza
season 2016-17, 2017-18, 2018-19, and 2019-20).
We then examined the risks (hazard ratios) for covid-19
versus influenza type A and type B, separately.
Because influenza A subtypes may vary by season,
we also examined the association of covid-19 versus
influenza type A in each season. We examined the
risks (hazard ratios) of outcomes for covid-19 versus
influenza in patients with a record of vaccination for
influenza and those without a record of vaccination.
We estimated the risks within 30 days of admission
to hospital and setting the time of positive test result
as time zero. We examined the risks (hazard ratios)
according to hospital bed occupancy and, separately,
according to ICU bed occupancy in covid-19 patients.
We updated the covariates during the follow-up
and did time dependent analyses. We applied the
overlap weighting method and the inverse probability
weighting method. To remove potentially nosocomially
acquired infections, we removed patients who had a
first positive test after admission to hospital and then
additionally removed those who had a first positive
test on the first day of admission. We did analyses in
subgroups based on sex, and, finally, we evaluated the
association in subgroups according to smoking status
and body mass index category.
We considered P values less than 0.05, 95%
confidence intervals of the hazard ratio or odds ratio
that did not cross 1, or 95% confidence intervals of the
length of stay difference or event rate difference that
did not cross 0 to be statistically significant. We used
SAS Enterprise Guide version 7.1 for all analyses.

Patient and public involvement
No patients were involved in developing the hypothesis,
the specific aims, or the research questions; nor
were they involved in developing plans for design
3
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and 2.02% of body mass index), we applied mean
imputation.
We also collected vital signs at admission, including
heart rate, temperature, respiratory rate, blood oxygen
concentration, systolic and diastolic blood pressure,
and laboratory measurements including white blood
cell count, hemoglobin, serum albumin, blood urea
nitrogen, platelet count, bicarbonate, and lymphocyte
percentage, on the basis of measurements during the
hospital admission and closest to admission date and
time.
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Results
A total of 12 676 people were admitted to hospital
with seasonal influenza between 1 January 2017 and
31 December 2019, and 3641 were admitted with
covid-19 between 1 February 2020 and 17 June 2020.
Table 1 describes the baseline demographic and health
characteristics. The percentage of black patients
admitted with covid-19 (49.8%) was more than double
the percentage admitted with seasonal influenza
(22.0%); the percentages of patients with obesity,
dementia, and diabetes mellitus were higher in the
covid-19 group. The percentages of people who were
current smokers or who had cancer, cardiovascular
disease, chronic lung disease, and use of angiotensin
converting enzyme inhibitors or angiotensin receptor
blockers and statins was higher in the seasonal
influenza group (table 1).
Differences in clinical manifestations of covid-19
versus seasonal influenza
We then comparatively evaluated the clinical
manifestations of covid-19 versus those of seasonal
influenza. Table 2 shows the number of events in
each group, the unadjusted and adjusted odds ratios,
and the excess number of outcomes per 100 patients
admitted to hospital with covid-19 compared with
seasonal influenza. Compared with people admitted to
hospital with seasonal influenza, we observed a graded
association between covid-19 and risk of acute kidney
injury; the odds of the association increased with
increasing severity of acute kidney injury, and we also
saw an increased risk of incident renal replacement
therapy. Covid-19 was also associated with increased
risk of incident insulin use, severe septic shock,
vasopressor use, pulmonary embolism, deep venous
thrombosis, stroke, acute myocarditis, arrythmias
and sudden cardiac death, elevated troponin,
elevated aspartate aminotransferase, elevated alanine
aminotransferase, and rhabdomyolysis.
Differences in risk of death and health resource use
for covid-19 versus seasonal influenza
Table 3 and table 4 show the number of deaths in each
group, unadjusted and adjusted hazard ratios, and the
number of excess deaths per 100 patients admitted
to hospital with covid-19 compared with seasonal
influenza. Compared with people admitted to hospital
with seasonal influenza, admission with covid-19 was
associated with increased risk of death; we observed
16.85 (95% confidence interval 14.85 to 18.99)
excess deaths per 100 patients due to covid-19. Health
resource use was much more pronounced for covid-19
compared with seasonal influenza. Covid-19 was
associated with significantly higher risk of mechanical
4

ventilation use, admission to ICU, and prolonged
length of hospital stay (table 3, table 4, fig 1, and fig 2).

Rates of death by age, race, and comorbid condition
Figure 3 and supplementary table S2a show estimated
rates of death with covid-19 by age, race, and comorbid
condition. Death rates were generally highest in older
and black individuals. Excess rates of death per
100 people with covid-19 (compared with seasonal
influenza) were most pronounced in adults older than
75 years with chronic kidney disease or dementia
and in black people with obesity, diabetes, or chronic
kidney disease (fig 3 and supplementary table S2b).
Sensitivity analyses
We did several sensitivity analyses to test the robustness
of our results (fig 4 and supplementary table S3).
Firstly, because mortality from seasonal influenza may
vary by season, we developed sensitivity analyses to
examine the risk of death and health resource use in
covid-19 patients compared with those admitted with
influenza in each season (2016-17, 2017-18, 201819, 2019-20) separately; the results were consistent.
Secondly, the results were also consistent when
we evaluated the risk of death and resource use for
covid-19 compared with influenza A and B, separately.
Thirdly, because subtypes of influenza A may have
differential effects on health outcomes and because
the predominant subtype of influenza A may vary by
season, we examined the association of covid-19 versus
influenza A in each season; the results suggested that
compared with influenza A, covid-19 was associated
with increased risk of health resource use and death
in each of the examined seasons (supplementary table
S4). Fourthly, the increased risk in covid-19 versus
seasonal influenza was observed in analyses in which
the reference group was those influenza patients who
received an influenza vaccine and, separately, those
who did not receive an influenza vaccine. Fifthly,
analyses that evaluated the risk of death in the first 30
days and, separately, analyses that considered the date
of testing positive for influenza or covid-19 as time zero
yielded consistent results.
Sixthly, because a putative relation may exist
between hospital bed occupancy—an indicator of
how overwhelmed the hospital system is—and health
outcomes, we examined the risk of death and health
resource use for covid-19 versus seasonal influenza
according to hospital bed occupancy (<20%, 20<40%, 40-<60%, and 60-77.82%, the maximum
observed hospital bed occupancy in our cohort) and,
separately, according to ICU bed occupancy (<20%,
20-<40%, 40-<60%, 60-<80%, and 80-102.38%,
the maximum observed ICU bed occupancy in our
cohort); the results were consistent with the primary
analyses. The distributions of occupancy of hospital
beds and ICU beds are provided in supplementary
figure S6. Seventhly, the results were also consistent
in time dependent analyses in which covariates were
updated during follow-up. Eighthly, we considered the
overlap weighting method and the inverse probability
doi: 10.1136/bmj.m4677 | BMJ 2020;371:m4677 | the bmj
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or implementation of the study. No patients were
involved in the interpretation or writing up of results.
The study was conceived, designed, and conducted
under the exigent circumstances of the covid-19
global pandemic, which precluded patient and public
engagement.
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Characteristics
Overall (n=16 317)
Baseline characteristics
Mean (SD) age, years
69.98 (12.91)
Sex:
Male
15 432 (94.6)
Female
885 (5.42
Race:
White
10 975 (67.3)
Black
4599 (28.2)
Other
743 (4.6)
Smoking:
Never
7673 (47.0)
Former
4420 (27.1)
Current
4224 (25.9)
Body mass index:
Underweight (<18.5)
550 (3.4)
Normal (18.5 to <25)
4093 (25.1)
Overweight (25 to <30)
4872 (29.9)
Obese (≥30)
6802 (41.7)
Mean (SD) eGFR, mL/min/1.73m2
63.51 (27.3)
Chronic kidney disease
6994 (42.9)
Cancer
2788 (17.1)
Cerebrovascular disease
2373 (14.5)
Cardiovascular disease
6134 (37.6)
Dementia
2403 (14.7)
Diabetes mellitus
7135 (43.7)
Hypertension
11 931 (73.1)
Chronic lung disease
6160 (37.8)
Peripheral artery disease
764 (4.7)
Statins
7511 (46.0)
ACE/ARB
5579 (34.2)
NSAIDs
1842 (11.29)
Selected vital signs on admission*
Median (IQR) heart rate, beats per min
87 (75-100)
Median (IQR) temperature, °C
36.9 (36.6-37.5)
Temperature >38°C
2161 (13.3)
Median (IQR) respiratory rate, breaths per min
18 (18-20)
Median (IQR) oxygen concentration, %
95 (93-97)
Oxygen concentration <95%
6104 (38.2)
Median (IQR) systolic blood pressure, mm Hg
131 (116-148)
Median (IQR) diastolic blood pressure, mm Hg
74 (65-82)
Selected laboratory measurements on admission*
Median (IQR) white blood cell count, ×109/L
7.1 (5.3-9.7)
Median (IQR) hemoglobin, g/L
131 (116-145)
Median (IQR) serum albumin, g/L
36 (31-39)
Median (IQR) blood urea nitrogen, mmol/L
6.8 (5.0-10.0)
Median (IQR) platelet count, ×109/L
185 (144-237)
Median (IQR) bicarbonate, mmol/L
25 (23-27)
Median (IQR) lymphocytes, %
12.7 (7.8-20.2)

Seasonal influenza
(n=12 676; 77.7%)

Covid-19 (n=3641;
22.3%)

70.25 (12.8)

69.03 (13.4)

11 994 (94.6)
682 (5.4)

3438 (94.4)
203 (5.6)

9318 (73.5)
2787 (22.0)
571 (4.5)

1657 (45.5)
1812 (49.8)
172 (4.7)

5694 (44.9)
3315 (26.2)
3667 (28.9)

1979 (54.4)
1105 (30.4)
557 (15.3)

441 (3.5)
3333 (26.3)
3829 (30.2)
5073 (40.0)
63.57 (26.6)
5425 (42.8)
2258 (17.8)
1817 (14.3)
5007 (39.5)
1693 (13.4)
5418 (42.7)
9277 (73.2)
5271 (41.6)
610 (4.8)
6114 (48.2)
4603 (36.3)
1439 (11.4)

109 (3.0)
760 (20.9)
1043 (28.7)
1729 (47.5)
63.30 (29.6)
1569 (43.1)
530 (14.6)
556 (15.37)
1127 (31.0)
710 (19.5)
1717 (47.2)
2654 (72.9)
889 (24.4)
154 (4.2)
1397 (38.4)
976 (26.8)
403 (11.1)

88 (76-101)
36.9 (36.6-37.5)
1627 (12.9)
18 (18-20)
95 (93-97)
4969 (40.0)
131 (116-148)
74 (65-82)

85 (75-97)
37.1 (34.4-36.7)
534 (14.9)
18 (18-20)
96 (94-98)
1135 (32.2)
131 (117-146)
75 (67-83)

<0.001
<0.001
0.002
<0.001
<0.001
<0.001
0.24
<0.001

7.4 (5.5-10.0)
131 (116-145)
36 (32-39)
6.8 (5.0-9.6)
182 (142-233)
25 (23-27)
11.9 (7.3-19.0)

6.2 (4.7-8.3)
131 (115-144)
35 (30-38)
7.1 (5.0-12.1)
193 (149-252)
25 (23-28)
15.8 (10.0-23.4)

0.001
0.02
<0.001
<0.001
<0.001
<0.001
<0.001

P value

<0.001
0.65

<0.001

<0.001

<0.001

0.63
0.75
<0.001
0.16
<0.001
<0.001
<0.001
0.72
<0.001
0.14
<0.001
<0.001
0.63

ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; eGFR=estimated glomerular filtration rate; IQR=interquartile range;
NSAID=non-steroidal anti-inflammatory drug.
*Vital signs and laboratory measurements recorded after and closest to admission date and time.

weighting method as two alternatives to our primary
approach (the doubly robust method); both alternative
methods yielded estimates consistent with the
primary approach. Ninthly, to eliminate concern about
nosocomially acquired seasonal influenza or covid-19
infections, we did analyses in which we removed
patients who had a positive test while in hospital
and restricted cohort entry to those with a positive
influenza or covid-19 test before and including the first
day of hospital admission; results were consistent with
those in the primary analyses and were also consistent
in analyses considering patients with a positive
the bmj | BMJ 2020;371:m4677 | doi: 10.1136/bmj.m4677

test before admission. Tenthly, because our cohort
comprised mostly male US veterans, and to examine
whether the observed associations were also evident
among female patients, we did analyses in subgroups
based on sex; the results were consistent in both
male and female subgroups. Finally, to test whether
the observed associations were evident in smokers
and non-smokers and, separately, among people
with normal weight and obesity, we evaluated the
association in subgroups according to smoking status
and body mass index category; the results suggested
that compared with seasonal influenza, covid-19 was
5
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Table 1 | Baseline and admission characteristics of patients admitted to hospital with seasonal influenza and
coronavirus disease 2019 (covid-19). Values are numbers (percentages) unless stated otherwise
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Clinical manifestations
Any acute kidney injury
Acute kidney injury stage 2 or above
Acute kidney injury stage 3
Incident renal replacement therapy§
Incident insulin use¶
Severe septic shock
Vasopressor use
Pulmonary embolism
Deep venous thrombosis
Stroke
Acute myocarditis
Arrythmias and sudden cardiac death
Troponin >0.4 ng/mL
Aspartate aminotransferase:
>40 IU/L
>5 times upper limit of normal**
Alanine aminotransferase:
>40 IU/L
>5 times upper limit of normal ††
Rhabdomyolysis:
CPK >1000 IU/L
CPK >5000 IU/L
CPK >5× upper limit of normal ‡‡

Seasonal influenza
(n=12 676)—No (%)
3670 (29.0)
638 (5.0)
408 (3.2)
113/12 128 (0.9)
1048/8484 (12.4)
300 (2.4)
613 (4.8)
262 (2.1)
285 (2.3)
124 (1.0)
10 (0.1)
275 (2.2)
654 (5.2)

Covid-19
(n=3641)—No (%)
1355 (37.2)
538 (14.8)
397 (10.9)
160/3430 (4.7)
555/2412 (23.0)
319 (8.8)
595 (16.3)
118 (3.2)
141 (3.9)
69 (1.9)
23 (0.6)
138 (3.8)
311 (8.5)

Unadjusted OR*
(95% CI)
1.46 (1.35 to 1.57)
3.27 (2.90 to 3.69)
3.68 (3.19 to 4.25)
5.20 (4.08 to 6.64)
2.12 (1.89 to 2.38)
3.96 (3.37 to 4.66)
3.84 (3.41 to 4.33)
1.59 (1.27 to 1.98)
1.75 (1.43 to 2.15)
1.96 (1.45 to 2.63)
8.05 (3.83 to 16.92)
1.78 (1.44 to 2.19)
1.73 (1.51 to 1.99)

Adjusted OR*†
(95% CI)
1.52 (1.37 to 1.69)
3.16 (2.74 to 3.64)
3.43 (2.90 to 4.06)
4.11 (3.13 to 5.40)
1.86 (1.62 to 2.14)
4.04 (3.38 to 4.83)
3.95 (3.46 to 4.51)
1.50 (1.18 to 1.90)
1.50 (1.20 to 1.88)
1.62 (1.17 to 2.24)
7.82 (3.53 to 17.36)
1.76 (1.40 to 2.20)
1.75 (1.50 to 2.05)

Excess outcomes per
100 patients*‡ (95% CI)
5.81 (5.35 to 6.27)
8.06 (6.49 to 9.85)
5.97 (4.57 to 7.66)
2.77 (1.63 to 4.63)
9.35 (8.31 to 10.29)
6.36 (4.48 to 8.87)
11.47 (9.10 to 14.22)
1.00 (0.59 to 1.69)
1.13 (0.69 to 1.83)
0.62 (0.30 to 1.25)
0.53 (0.11 to 2.63)
1.57 (0.97 to 2.51)
3.37 (2.50 to 4.47)

3694 (29.1)
279 (2.2)

2104 (57.8)
204 (5.6)

3.33 (3.08 to 3.59)
2.64 (2.19 to 3.17)

3.16 (2.91 to 3.43)
2.38 (1.94 to 2.91)

27.00 (26.00 to 27.71)
2.90 (1.90 to 4.35)

3154 (24.9)
311 (2.5)

1697 (46.6)
309 (8.5)

2.64 (2.44 to 2.84)
3.46 (2.95 to 4.06)

2.65 (2.43 to 2.88)
3.33 (2.80 to 3.97)

21.12 (19.81 to 22.26)
5.54 (3.90 to 7.76)

411 (3.2)
94 (0.7)
288 (2.3)

274 (7.5)
43 (1.2)
181 (5.0)

2.43 (2.08 to 2.84)
1.60 (1.11 to 2.30)
2.25 (1.86 to 2.72)

1.84 (1.54 to 2.18)
1.20 (0.81 to 1.77)
1.66 (1.35 to 2.04)

2.65 (1.87 to 3.72)
0.15 (−0.06 to 0.42)
1.53 (0.98 to 2.35)

CPK=creatine phosphokinase; OR=odds ratio.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, and non-steroidal antiinflammatory drugs.
‡Excess outcomes per 100 patients due to covid-19 compared with seasonal influenza.
§Among patients without history of renal replacement therapy before hospital admission (n=15 558).
¶Among patients without history of diabetes treatment before hospital admission (n=10 896).
**Defined as 240 IU/L for males and 215 IU/L for females.
††Defined as 165 IU/L for males and 125 IU/L for females.
‡‡Defined as 1540 IU/L for males and 960 IU/L for females.

associated with increased risk of death and health
resource use regardless of smoking and body mass
index status (fig 4 and supplementary table S3).

Discussion
In this work, we provide a comparative evaluation
of the clinical manifestations and outcomes in a
national cohort of patients admitted to hospital with
covid-19 or seasonal influenza. Our results suggest
that compared with seasonal influenza, covid-19
was associated with higher risk of acute kidney

injury, incident renal replacement therapy, incident
insulin use, severe septic shock, vasopressor use,
pulmonary embolism, deep venous thrombosis,
stroke, acute myocarditis, arrythmias and sudden
cardiac death, elevated troponin, elevated aspartate
aminotransferase, elevated alanine aminotransferase,
and rhabdomyolysis. Covid-19 was also associated
with increased risk of death, need for mechanical
ventilation, and admission to ICU and prolonged length
of hospital stay. Excess rates of death for covid-19 (in
excess of those for seasonal influenza) were highest in

Table 3 | Risks of death and healthcare resource use in patients admitted to hospital with coronavirus disease 2019 (covid-19) versus seasonal
influenza
Outcomes

Death
Mechanical ventilator use¶
ICU admission¶

Measure
No (%)
Median (IQR) days till event§
No (%)
Median (IQR) days till event**
No (%)
Median (IQR) days till event††

Seasonal influenza
(n=12 676)
674 (5.3)
18 (6-17)
529 (4.2)
1 (0-4)
2353 (18.6)
1 (0-5)

Covid-19
(n=3641)
676 (18.6)
10 (6-17)
545 (15.0)
2 (0-5)
1341 (36.8)
0 (0-4)

Unadjusted HR*
(95% CI)

Adjusted HR*†
(95% CI)

Excess outcomes per 100
patients*‡ (95% CI)

4.55 (4.09 to 5.07)

4.97 (4.42 to 5.58)

16.85 (14.85 to 18.99)

3.93 (3.49 to 4.42)

4.01 (3.53 to 4.54)

11.29 (9.62 to 13.14)

2.30 (2.16 to 2.46)

2.41 (2.25 to 2.59)

19.80 (17.81 to 21.87)

HR=hazard ratio; ICU=intensive care unit; IQR=interquartile range.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, and non-steroidal antiinflammatory drugs.
‡Excess outcome per 100 patients due to covid-19 compared with seasonal influenza.
§ Among patients who died.
¶Death before event was considered as competing risk.
**Among patients who used mechanical ventilation.
††Among patients who had ICU admission.
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Table 2 | Clinical manifestations in patients admitted to hospital with seasonal influenza and coronavirus disease 2019 (covid-19)
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Outcome
Length of hospital
stay, days

Measure
Median (IQR)
Mean (SD)

Seasonal influenza
(n=12 388)
3 (2-6)
7 (19.00)

Covid-19
(n=2621)
6 (3-12)
10 (10.99)

Unadjusted days
difference* (95% CI)

Adjusted days difference*†
(95% CI)

3.11 (2.36 to 3.7)

3.00 (2.20 to 3.80)

IQR=interquartile range.
*Seasonal influenza group served as reference.
†Models adjusted for age, sex, race, smoking status, body mass index, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular
disease, cerebrovascular disease, dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of statins, angiotensin converting enzyme
inhibitors/angiotensin II receptor blockers, and non-steroidal anti-inflammatory drugs.

adults older than 75 years with chronic kidney disease
and dementia and in black patients with obesity,
diabetes mellitus, and chronic kidney disease. The
results were robust to challenge in multiple sensitivity
analyses.

Cumulative incidence
of death per 100 patients

Contextual evaluation of findings
As our understanding of covid-19 is evolving, the
fact that, although the virus preferentially infects
cells in the respiratory tract, it may also be detected
20

Death
Seasonal inﬂuenza
Covid-19

15
10
5

Cumulative incidence of mechanical
ventilator use per 100 patients

20

Cumulative incidence of ICU
admission per 100 patients

0

40

Mechanical ventilator use

15
10
5
0
Admission to intensive care

30
20
10
0
0

10

20

30

40

50

60
Days

Fig 1 | Adjusted cumulative incidence rate (with 95% CI) of death, mechanical ventilator
use, and admission to intensive care unit (ICU) per 100 patients admitted to hospital
with seasonal influenza and coronavirus disease 2019 (covid-19)
the bmj | BMJ 2020;371:m4677 | doi: 10.1136/bmj.m4677

in multiple organs, suggesting broad extrapulmonary
organotropism, is becoming increasingly clear.22 23
Covid-19 seems to have a kidney tropic effect; early
observations suggested high rates of acute kidney
injury and need for renal replacement therapy among
patients with covid-19.22-25 Here, we show that risks
of acute kidney injury and incident renal replacement
therapy were higher with covid-19 than seasonal
influenza. In our cohort, 15.0% of patients with
covid-19 needed mechanical ventilation, generally
consistent with the range of 12% to 24% reported
in other US studies of covid-19.26-28 Recent reports
suggested a bidirectional relation between covid-19
and diabetes mellitus, in that diabetes may predispose
to covid-19 and that a diagnosis of covid-19 may result
in derangement in insulin and glucose homeostasis
and new onset of diabetes.29 30 Our findings of higher
risk of incident insulin use among patients who were
not taking any treatment for diabetes mellitus before
hospital admission with covid-19 suggests the need for
greater attention to management of glucose in patients
with covid-19 and the need for long term follow-up to
gain a better understanding of the chronicity of these
acute disturbances in glucose homeostasis.29 Risks
of severe septic shock and vasopressor use were also
higher in the covid-19 group, consistent with reports of
septic shock in patients with covid-19.31 We also report
increased risk of pulmonary embolism, deep venous
thrombosis, and stroke compared with seasonal
influenza; clarity about the underlying biologic
mechanism of a prothrombotic hypercoagulable state
in covid-19 is evolving.32-36 The findings of increased
risk of acute myocarditis, arrythmias and sudden
cardiac death, and elevated troponin suggest that
covid-19 may portend serious cardiac complications.
Risk of elevated transaminases and rhabdomyolysis
was also increased among patients with covid-19; the
underlying pathophysiology of these abnormalities is
not yet entirely clear. Our approach for the comparative
evaluation of the acute clinical manifestations of
covid-19 versus seasonal influenza was based on a
priori knowledge; however, as our understanding
of the clinical manifestations of covid-19 deepens,
additional important differences in the clinical
sequalae of these two diseases may come to light and
may be investigated in future research.
Many of the acute clinical manifestations of covid-19
described in this report are disease states that need
chronic management (for example, new onset diabetes,
stroke). This is compounded by emerging evidence
7
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Table 4 | Length of hospital stay in patients admitted to hospital with coronavirus disease 2019 (covid-19) versus
seasonal influenza, among patients discharged from hospital (n=15 009)
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Covid-19 v
seasonal inﬂuenza
Adjusted hazard
ratio (95% CI)

Death
Mechanical ventilator use
Intensive care unit admission

16.85 (14.85 to 18.99)
11.29 (9.62 to 13.14)
19.80 (17.81 to 21.87)
1

Group

Excess outcomes
per 100 patients
(95% CI)

2

3

4

5

6

Adjusted length
of stay (days)

Seasonal inﬂuenza
Covid-19

Additional length of
stay (days) (95% CI)

3.00 (2.20 to 3.80)
0 2 4 6 8 10 12

Fig 2 | Risks of death and healthcare resource use in patients admitted to hospital with
coronavirus disease 2019 (covid-19) versus seasonal influenza. Models were adjusted
for age, sex, race, smoking status, body mass index, estimated glomerular filtration
rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, peripheral artery disease, and use of
statins, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers and
non-steroidal anti-inflammatory drugs. Seasonal influenza group served as reference
for each model. Length of hospital stay was calculated within patients discharged from
hospital (n=15 009)

suggesting that some acute symptoms of covid-19 may
linger far beyond the acute illness and that recovery may
be protracted and incomplete in many “long haulers.”
Taken together, these observations suggest that,
beyond the acute setting, a greater understanding of
the long term health trajectories of patients with “long
covid-19” and care strategies to optimize wellness and
reduce the burden of chronic and permanent health
loss are needed to lessen the overall health, societal,
and economic toll of this pandemic.
We observed much higher rates of death among
patients admitted to hospital with covid-19 than with

seasonal influenza. We also report that in adjusted
models using the doubly robust approach, the risk of
death in covid-19 patients was nearly fivefold higher
than in those in the seasonal influenza group. We
estimated that compared with seasonal influenza,
covid-19 was associated with 16.85 (95% confidence
interval 14.85 to 18.99) excess deaths per 100 patients.
Our results also suggest significantly increased risk
of mechanical ventilation use, ICU admission, and
prolonged length of stay. Our estimates provide
an “apples with apples” comparative quantitative
assessment of the magnitude of risk of death (and other
health outcomes) in patients admitted to hospital with
covid-19 and seasonal influenza. The estimates may
help to inform efforts to manage the ongoing covid-19
global pandemic in which some surge in activity (wave)
may coincide with seasonal influenza.
Our heatmap approach, which provides adjusted
estimates of the rates of death by age, race, and
comorbid condition, shows that differences in rates of
death between covid-19 and seasonal influenza (excess
rates of death in covid-19) are most pronounced in
older adults, among black people, and in those with
dementia, diabetes mellitus, obesity, and kidney
disease, suggesting that a more targeted prevention
effort aimed at these high risk populations may be
needed to reduce mortality rates.
Several other considerations merit discussion.
Although we balanced the two groups according to
demographic and health characteristics to optimize the
comparative evaluation of the clinical characteristics
and outcomes of covid-19 versus seasonal influenza,
increased awareness of covid-19 may have resulted in
greater ascertainment of covid-19 infections, whereby
less severe cases of covid-19 relative to seasonal
influenza would be diagnosed and possibly admitted
to hospital, and relatively less historical ascertainment
of seasonal influenza, whereby milder influenza cases
may not have been diagnosed, enriching the seasonal

Deaths
Overall

≤65

65-75

Excess deaths
>75

White

Black

Overall

≤65

65-75

>75

White

Black

Overall
Cancer
Chronic lung disease
Cardiovascular disease
Hypertension
Diabetes mellitus
Obesity
Cerebrovascular disease
Peripheral artery disease
Chronic kidney disease
Dementia
Deaths per 100 patients

Excess deaths per 100 patients
10

15

20

25

30

35

5

10

15

20

25

30

Fig 3 | Rates of death in patients admitted to hospital with coronavirus disease 2019 (covid-19) (left), and excess deaths compared with patients
admitted with seasonal influenza (right), by age (≤65, 65-75, >75 years), race (white, black), and comorbid condition. Number in each cell represents
rate of death or excess deaths per 100 patients admitted with covid-19, given conditions. Lighter colored cells indicate lower death rates or smaller
differences, and darker colored cells indicate higher death rates or larger differences
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Outcome
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Covid-19 v seasonal inﬂuenza: hazard ratio (95% CI)
Mechanical
ventilation

Death

ICU
admission

Inﬂuenza season
2016-17†
2017-18‡
2018-19§
2019-20¶
Inﬂuenza
Type A
Type B
Inﬂuenza type A season
2016-17†
2017-18‡
2018-19§
2019-20¶
Inﬂuenza vaccine
Yes
No
Outcome within 30 days
Positive test date as T0
Hospital occupancy (%)
0 to <20
20 to <40
40 to <60
60 to 77.82
Intensive care unit occupancy (%)
0 to <20
20 to <40
40 to <60
60 to <80
80 to 102.38
Time dependent analyses
Overlap weighting
Inverse probability weighting
Time of positive covid-19/inﬂuenza test
Before or at date of hospital admission
Before date of hospital admission
Sex
Male
Female
Smoking status
Never smoker
Former smoker
Current smoker
BMI category
18.5 to <25
25 to <30
≥30
1

4

7

10

13

1

4

7

10

1

4

7

10

Fig 4 | Risks of death and healthcare resource use in patients admitted to hospital with coronavirus disease 2019 (covid-19) versus seasonal
influenza. Seasonal influenza group served as reference. BMI=body mass index; ICU=intensive care unit; T0=time zero. *Models adjusted for age,
sex, race, smoking status, BMI, estimated glomerular filtration rate, chronic lung disease, cancer, cardiovascular disease, cerebrovascular disease,
dementia, diabetes mellitus, hypertension, peripheral artery disease, use of statins, angiotensin converting enzyme inhibitors/angiotensin II
receptor blockers, and non-steroidal anti-inflammatory drugs. †Included seasonal influenza patients between 1 Jan 2017 and 31 Aug 2017 in cohort.
‡Included seasonal influenza patients between 1 Sept 2017 and 31 Aug 2018 in cohort. §Included seasonal influenza patients between 1 Sept 2018
and 31 Aug 2019 in cohort. ¶Included seasonal influenza patients between 1 Sept 2019 and 31 Dec 2019 in cohort
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Sensitivity analyses*
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Limitations and strengths of study
This study has several limitations. We relied on data
from electronic health records to do this comparative
evaluation, and, although we used validated
definitions, inaccurate measurements of variables
and misclassification bias may not be completely
eliminated. We used a doubly robust approach to
examine the risk of clinical manifestations and health
outcomes for covid-19 versus seasonal influenza,19 but
we cannot completely exclude the possibility of residual
10

confounding. Our cohort comprised US veterans who
were admitted to hospital for seasonal influenza or
covid-19 and included mostly older white males,
so our results may not be generalizable to broader
populations such as younger and healthier people.
Although we provide estimates of the adjusted absolute
rates of death according to age, race, and comorbid
condition to facilitate comparative evaluation of risk in
these groups, absolute rates may be lower in younger
and healthier populations. Our evaluation included
a comparative assessment of clinical manifestations
and outcomes of seasonal influenza and covid-19;
however, a pandemic influenza may have different
clinical manifestations and outcome profile. Finally, as
this pandemic continues to evolve, our understanding
of the epidemiology, clinical characteristics, and
outcomes of covid-19 will continue to evolve; in
particular, we note that care of covid-19 patients is
evolving rapidly, including discovery and use of new
therapeutics, and a vaccine is anticipated sometime
soon. Both drivers (improved care and vaccine
availability) will likely result in amelioration of health
outcomes among people with covid-19.
The study also has several strengths. We designed the
study to evaluate risk of death among people admitted
to hospital with covid-19 and seasonal influenza in
the same nationally integrated healthcare delivery
system designed to give equal access to care for eligible
veterans, which enhances the ability to establish a
comparative evaluation of risk. The multidimensional
nature and depth of VA data facilitate ascertainment
of medical conditions not only through diagnostic
or procedure codes but also through laboratory data
(for example, serum creatinine to define acute kidney
injury, estimated glomerular filtration rate to define
chronic kidney disease, creatine phosphokinase to
define rhabdomyolysis), vital signs (including body
mass index), vital status, and medication records (for
example, vasopressor use, insulin requirements).
Finally, we used a doubly robust approach to examine
the association between exposures and outcomes,
and our results were robust to challenge in multiple
sensitivity analyses including the application of two
alternative methods (overlap weighting method and
inverse probability weighting method).

Conclusions
In sum, our results suggest that compared with patients
admitted to hospital with seasonal influenza, those
admitted with covid-19 have increased risk of systemic
clinical manifestations (including higher risk of acute
kidney injury, incident renal replacement therapy,
incident insulin use, severe septic shock, vasopressor
use, pulmonary embolism, deep venous thrombosis,
stroke, acute myocarditis, arrythmias and sudden
cardiac death, elevated troponin, elevated aspartate
aminotransferase, elevated alanine aminotransferase,
and rhabdomyolysis), increased risk of death, and
higher need for healthcare resources (mechanical
ventilation, ICU admission, length of hospital stay).
Rates of death for covid-19 in excess of rates for
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influenza group with relatively sicker patients and
resulting in underestimation of the risk of outcomes
in covid-19 compared with seasonal influenza. Also,
relaxed admission criteria and reduced threshold
for admission in the covid-19 era—primarily driven
by heightened concerns about the virus—may have
resulted in admission of less sick people with covid-19,
which may have resulted in underestimation of risk of
covid-19 versus seasonal influenza. Health outcomes
of patients admitted to hospital may deteriorate as
hospitals become overwhelmed; if this existed in our
data, it may have resulted in overestimation of the
risk of adverse outcomes in covid-19 versus seasonal
influenza. However, although the pandemic exacted
a serious challenge to the VA hospital system, our
examination of weekly average bed occupancy and
weekly average ICU bed occupancy did not suggest that
the system was substantially strained (supplementary
figure S6), and we consistently observed that covid-19
was associated with increased risk of adverse
outcomes regardless of level of occupancy and the
excess risk was evident even in low occupancy. In
our comparative evaluation, we considered several
seasons of influenza, and the predominant subtype
of seasonal influenza may vary by season; influenza
A (H3N2) predominated in 2016-17 and 2017-18,
influenza A(H1N1)pdm09 predominated in 201819, and influenza B predominated early in the 201920 season. H3N2 predominant seasons have been
associated with more severe illness and mortality,
especially in older adults, relative to seasons during
which H1N1 or B viruses predominated.37 38 In our
evaluation, we did not identify appreciable differences
in risk of covid-19 versus seasonal influenza by season
or by influenza type (A or B). However, our data did not
contain enough information to allow a comparative
evaluation according to influenza subtype; evaluation
of the risks of death, mechanical ventilation, and
ICU admission for covid-19 versus influenza type A
by season yielded consistently higher risk of adverse
events for covid-19. Effect of sex, body mass index, and
smoking status on health outcomes may be different in
covid-19 and seasonal influenza.39-45 Our analyses of
subgroups based on sex, body mass index category,
and smoking status showed consistently that covid-19
was associated with worse outcomes than seasonal
influenza, but further studies are needed to gain a
fuller understanding of how these characteristics may
differentially influence health outcomes in patients
with covid-19 and seasonal influenza.
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